361 related articles for article (PubMed ID: 24342526)
1. Myostatin signaling regulates Akt activity via the regulation of miR-486 expression.
Hitachi K; Nakatani M; Tsuchida K
Int J Biochem Cell Biol; 2014 Feb; 47():93-103. PubMed ID: 24342526
[TBL] [Abstract][Full Text] [Related]
2. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.
Trendelenburg AU; Meyer A; Rohner D; Boyle J; Hatakeyama S; Glass DJ
Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1258-70. PubMed ID: 19357233
[TBL] [Abstract][Full Text] [Related]
3. Rheb, an activator of target of rapamycin, in the blackback land crab, Gecarcinus lateralis: cloning and effects of molting and unweighting on expression in skeletal muscle.
MacLea KS; Abuhagr AM; Pitts NL; Covi JA; Bader BD; Chang ES; Mykles DL
J Exp Biol; 2012 Feb; 215(Pt 4):590-604. PubMed ID: 22279066
[TBL] [Abstract][Full Text] [Related]
4. The type 1 insulin-like growth factor receptor (IGF-IR) pathway is mandatory for the follistatin-induced skeletal muscle hypertrophy.
Kalista S; Schakman O; Gilson H; Lause P; Demeulder B; Bertrand L; Pende M; Thissen JP
Endocrinology; 2012 Jan; 153(1):241-53. PubMed ID: 22087027
[TBL] [Abstract][Full Text] [Related]
5. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.
Glass DJ
Curr Top Microbiol Immunol; 2010; 346():267-78. PubMed ID: 20593312
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle.
Amirouche A; Durieux AC; Banzet S; Koulmann N; Bonnefoy R; Mouret C; Bigard X; Peinnequin A; Freyssenet D
Endocrinology; 2009 Jan; 150(1):286-94. PubMed ID: 18801898
[TBL] [Abstract][Full Text] [Related]
7. Akt/mTOR pathway contributes to skeletal muscle anti-atrophic effect of aerobic exercise training in heart failure mice.
Bacurau AV; Jannig PR; de Moraes WM; Cunha TF; Medeiros A; Barberi L; Coelho MA; Bacurau RF; Ugrinowitsch C; Musarò A; Brum PC
Int J Cardiol; 2016 Jul; 214():137-47. PubMed ID: 27060274
[TBL] [Abstract][Full Text] [Related]
8. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt.
Morissette MR; Cook SA; Buranasombati C; Rosenberg MA; Rosenzweig A
Am J Physiol Cell Physiol; 2009 Nov; 297(5):C1124-32. PubMed ID: 19759331
[TBL] [Abstract][Full Text] [Related]
9. Guanidinoacetic Acid Regulates Myogenic Differentiation and Muscle Growth Through miR-133a-3p and miR-1a-3p Co-mediated Akt/mTOR/S6K Signaling Pathway.
Wang Y; Ma J; Qiu W; Zhang J; Feng S; Zhou X; Wang X; Jin L; Long K; Liu L; Xiao W; Tang Q; Zhu L; Jiang Y; Li X; Li M
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30235878
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation.
Song YH; Godard M; Li Y; Richmond SR; Rosenthal N; Delafontaine P
J Investig Med; 2005 Apr; 53(3):135-42. PubMed ID: 15921033
[TBL] [Abstract][Full Text] [Related]
11. miR-199a-3p is involved in estrogen-mediated autophagy through the IGF-1/mTOR pathway in osteocyte-like MLO-Y4 cells.
Fu J; Hao L; Tian Y; Liu Y; Gu Y; Wu J
J Cell Physiol; 2018 Mar; 233(3):2292-2303. PubMed ID: 28708244
[TBL] [Abstract][Full Text] [Related]
12. Myostatin regulates miR-431 expression via the Ras-Mek-Erk signaling pathway.
Wu R; Li H; Li T; Zhang Y; Zhu D
Biochem Biophys Res Commun; 2015 May; 461(2):224-9. PubMed ID: 25869071
[TBL] [Abstract][Full Text] [Related]
13. Progranulin compensates for blocked IGF-1 signaling to promote myotube hypertrophy in C2C12 myoblasts via the PI3K/Akt/mTOR pathway.
Hu SY; Tai CC; Li YH; Wu JL
FEBS Lett; 2012 Sep; 586(19):3485-92. PubMed ID: 22967900
[TBL] [Abstract][Full Text] [Related]
14. Myostatin inactivation increases myotube size through regulation of translational initiation machinery.
Rodriguez J; Vernus B; Toubiana M; Jublanc E; Tintignac L; Leibovitch S; Bonnieu A
J Cell Biochem; 2011 Dec; 112(12):3531-42. PubMed ID: 21769921
[TBL] [Abstract][Full Text] [Related]
15. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways.
Rommel C; Bodine SC; Clarke BA; Rossman R; Nunez L; Stitt TN; Yancopoulos GD; Glass DJ
Nat Cell Biol; 2001 Nov; 3(11):1009-13. PubMed ID: 11715022
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle.
Joassard OR; Amirouche A; Gallot YS; Desgeorges MM; Castells J; Durieux AC; Berthon P; Freyssenet DG
Int J Biochem Cell Biol; 2013 Nov; 45(11):2444-55. PubMed ID: 23916784
[TBL] [Abstract][Full Text] [Related]
17. IGF and myostatin pathways are respectively induced during the earlier and the later stages of skeletal muscle hypertrophy induced by clenbuterol, a β₂-adrenergic agonist.
Abo T; Iida RH; Kaneko S; Suga T; Yamada H; Hamada Y; Yamane A
Cell Biochem Funct; 2012 Dec; 30(8):671-6. PubMed ID: 22696074
[TBL] [Abstract][Full Text] [Related]
18. Altered REDD1, myostatin, and Akt/mTOR/FoxO/MAPK signaling in streptozotocin-induced diabetic muscle atrophy.
Hulmi JJ; Silvennoinen M; Lehti M; Kivelä R; Kainulainen H
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E307-15. PubMed ID: 22068602
[TBL] [Abstract][Full Text] [Related]
19. MiRNA-199a-3p regulates C2C12 myoblast differentiation through IGF-1/AKT/mTOR signal pathway.
Jia L; Li YF; Wu GF; Song ZY; Lu HZ; Song CC; Zhang QL; Zhu JY; Yang GS; Shi XE
Int J Mol Sci; 2013 Dec; 15(1):296-308. PubMed ID: 24378853
[TBL] [Abstract][Full Text] [Related]
20. Role of IGF-I in follistatin-induced skeletal muscle hypertrophy.
Barbé C; Kalista S; Loumaye A; Ritvos O; Lause P; Ferracin B; Thissen JP
Am J Physiol Endocrinol Metab; 2015 Sep; 309(6):E557-67. PubMed ID: 26219865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
